DDInter1420 DDInter1676
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pentamidine {u} (Compound) resembles {v} (Compound) Ospemifene
Pentamidine {u} (Compound) binds {v} (Gene) S100B
Pentamidine {u} (Compound) upregulates {v} (Gene) CDK7
Pentamidine {u} (Compound) downregulates {v} (Gene) TYMS
Pentamidine {u} (Compound) causes {v} (Side Effect) Azotaemia
Pentamidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Galantamine
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Pentamidine (Compound) resembles Ospemifene (Compound)
Pentamidine (Compound) binds S100B (Gene)
Pentamidine (Compound) upregulates CDK7 (Gene)
Pentamidine (Compound) downregulates TYMS (Gene)
Pentamidine (Compound) causes Azotaemia (Side Effect)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Galantamine
Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Pentamidine may lead to a major life threatening interaction when taken with Bexarotene